Latest China Market News

The a2 Milk Company has clinched final Chinese regulatory approval to rebrand infant formula products under its flagship a2™ label, completing a pivotal acquisition step. The company plans to launch these products later in 2026 and is poised to declare a $300 million special dividend.

Vita Life Sciences projects a slight increase in H1 2026 sales and stable pre-tax profits, supported by strong markets in Australia and Malaysia/Singapore but offset by regulatory headwinds in China.

Xenitra Limited’s OPAL Real World Asset tokenised sales ecosystem has accelerated rapidly, crossing $1.1 million in product sales and onboarding over 400 distribution partners within seven weeks, signalling strong traction in Greater China.

Osteopore has secured Hainan FDA approval to clinically use and sell its custom orthopaedic devices at Shanghai Ruijin Hospital’s Hainan branch, marking a key step towards wider China market access. The company has scheduled its first patient surgery for June 2026.

Appen Limited's FY25 results reveal solid revenue growth driven by generative AI projects and a standout performance from its China segment. The company sets FY26 revenue guidance of $270-300 million, underpinned by operational efficiencies and expanding AI data services.

BLIS Technologies posted a 16% revenue increase to $14.7 million in FY26, resolving a key intellectual property dispute and expanding strategic partnerships, including an extended Probi AB agreement that now covers pet nutrition.

Xenitra Limited's OPAL Real World Asset tokenised sales ecosystem has generated over $500,000 in sales within its first month, onboarding more than 130 distributors and positioning the company as an early mover in blockchain-enabled FMCG sales in China.

Murray Cod Australia (ASX:MCA) is raising $18.6 million through a fully underwritten entitlement offer at a steep 43% discount to last price, aiming to convert its record 3,700-tonne biomass into sales and expand processing capacity.

Merino & Co. has secured a three-year exclusive distribution agreement in Mainland China, guaranteeing a minimum annual order of CNY 30 million (~AUD 6.5 million) and targeting 20% yearly growth upon renewal.

Merino & Co. reported Q3 FY26 revenue of A$441,558 with new domestic and China purchase orders supporting its growth strategy, while cash reserves fell to A$654,282 due to investments in production and marketing.

Australian Strategic Materials reports a 70% surge in NdFeB alloy production, installs pilot heavy rare earth furnace, and progresses its acquisition by Energy Fuels with regulatory approvals underway.

Xenitra Limited has acquired Hong Kong Fukang Trading Co., including key pharmaceutical licenses and ecommerce assets, to fully operationalise its OTC medicine business in Hong Kong and China.